tiprankstipranks
In this article:
Blurbs

Leerink Partners Sticks to Their Buy Rating for Guardant Health (GH)

In this article:
In this article:

In a report issued on March 8, Puneet Souda from Leerink Partners maintained a Buy rating on Guardant Health (GHResearch Report). The company’s shares closed last Wednesday at $60.29, close to its 52-week low of $53.00.

According to TipRanks.com, Souda is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -5.9% and a 37.4% success rate. Souda covers the Healthcare sector, focusing on stocks such as AbCellera Biologics, Castle Biosciences, and Twist Bioscience.

Currently, the analyst consensus on Guardant Health is a Strong Buy with an average price target of $121.50, implying an 110.7% upside from current levels. In a report issued on February 24, J.P. Morgan also maintained a Buy rating on the stock with a $150.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $169.43 and a one-year low of $53.00. Currently, Guardant Health has an average volume of 1.13M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Guardant Health, Inc. is a precision oncology company, which engages in provision of precision oncology testing and development services. It focuses performing blood tests, vast data sets, and advanced analytics to conquer cancer. The company was founded by Helmy Eltoukhy and AmirAli H. Talasaz in 2012 and is headquartered in Redwood City, CA.

Read More on GH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed

In this article:

Latest News Feed